What are the chemotherapy regimens used to treat recurrent platinum-sensitive fallopian tube carcinoma?

Updated: Aug 20, 2019
  • Author: from Memorial Sloan-Kettering - Elizabeth L Jewell, MD, MHSc; Chief Editor: from Memorial Sloan-Kettering - Yukio Sonoda, MD  more...
  • Print
Answer

Answer

Platinum-sensitive disease:

A disease-free interval of at least 6 months constitutes platinum-sensitive disease. These patients have been re-treated with platinum-based chemotherapy. Most patients are re-treated with a platinum doublet. Single-agent treatment is the preferred approach for platinum-resistant patients or intermediate platinum-sensitive patients with a short time to recurrence (6-12 months).

  • Paclitaxel 135-175 mg/m2 IV infused over 3 h plus  carboplatin AUC 5-6 IV infused over 1 h every 21 d for six cycles [8, 12] or

  • Docetaxel 60-75 mg/m2 IV infused over 1 h plus  carboplatin AUC 5 IV infused over 1 h every 21 d for three to six cycles [7, 12] or

  • Pegylated liposomal doxorubicin 30 mg/m2 IV infused over 30 min plus carboplatin AUC 5 IV every 21 d for six cycles [13] or

  • Gemcitabine 1000 mg/m2 IV on days 1 and 8 plus  carboplatin AUC 4 on day 1 every 21 d for six cycles [14] or

  • Carboplatin AUC 6 IV push once every 3 weeks with paclitaxel 80 mg/m2 IV infused over 3 h every week [15]

Consideration may be given to bevacizumab, in combination with carboplatin and paclitaxel [16] or with carboplatin and gemcitabine [17] , followed by bevacizumab alone, as follows:

  • Bevacizumab (15 mg/kg IV on Day 1) plus  carboplatin IV (AUC 5 on Day 1) plus  paclitaxel (175 mg/m 2 IV on Day 1) every 21 days for 6 cycles and up to 8 cycles, followed by continued use of bevacizumab 15 mg/kg every 21 days as a single agent [16] or
  • Bevacizumab (15 mg/kg IV on Day 1) plus carboplatin IV (AUC 4 on Day 1) plus gemcitabine (1000 mg/m 2 IV on Days 1 and 8) every 21 days for 6 cycles and up to 10 cycles, followed by continued use of bevacizumab 15 mg/kg every 21 days as a single agent until disease progression [17]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!